VRUS—Looks like the trial has only been pushed back.
In biotech, this kind of purported delay without cause is often employed as a means of saving face. I’ll make you a gentleman’s bet that the phase-2b trial in gentotyoe-2/3 patients never starts.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”